CD33 and acute myeloid leukemia: A DNA-alkylating antitumor agent was conjugated to a humanized anti-CD33 antibody using sulfo-N-Succinimidyl 4-(2-pyridyldithio)-butanoate to form a CD33-targeting ADC for the treatment of acute myeloid leukemia (AML) [116].